Anakinra for the treatment of neonatal-onset multisystem inflammatory disease: Commentary

Nature Clinical Practice Rheumatology

Volumn 2, Issue 12, 2006, Pages 646-647

  Hoffman, Hal M ^a   Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CASPASE INHIBITOR; CORTICOSTEROID; CRYOPYRIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GENE PRODUCT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A;

ABSENCE OF SIDE EFFECTS; CINCA SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ERYTHROCYTE SEDIMENTATION RATE; GENE MUTATION; HUMAN; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT FAILURE; TREATMENT OUTCOME; URTICARIA;

EID: 33751536064     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0350     Document Type: Short Survey

References (5)

1. Agostini L et al. (2004) NALP3 forms an IL-1betaprocessing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20: 319-325
2. Zwerina J et al. (2005) Pathogenesis of rheumatoid arthritis: Targeting cytokines. Ann NY Acad Sci 1051: 716-729
3. Dinarello C (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355-1359
4. Martinon F et al. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241
5. Hoffman HM et al. (2004) Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779-1785